Effects of Green Cardamom Supplementation on Obesity and Diabetes Gene Expression Among Obese Women With Polycystic Ovary Syndrome; A Double Blind Randomized Controlled Trial

Abstract

BackgroundPolycystic ovary syndrome (PCOS) is an endocrine disease in which related obesity, metabolic disorders and is considered as one of the main causes of infertility in women. This trial was investigated the effects of green cardamom on obesity and diabetes genes expression among obese women with PCOS.Methods194 PCOS women were randomly divided two groups: intervention (n= 99; 3 g/day green cardamom) and control groups (n=95). All of them were given low calorie diet. Anthropometric, glycemic and androgen hormones were assessed before and after 16 weeks’ intervention. Fat mass and obesity-associated (FTO), Peroxisome proliferative activating Receptor-γ (PPAR-γ) Carnitine Palmitoyltransferase 1A (CPT1A), Acetyl-CoA Carboxylase Beta (ACAB), Leptin Receptor (LEPR), Gherlin, and lamin A/C (LAMIN) genes in PBMC were measured in each group using reverse transcription-polymerase chain reaction (RT-PCR) method.ResultsAnthropometric indices were significantly decreased after intervention in both two studied groups. Glycemic indices and androgen hormones were significantly improved in the intervention group. The expression level of FTO, CPT1A, LEPR, and LAMIN were significantly down-regulated (P<0.001), as well as, PPAR-y was significantly up-regulated in the intervention group after intervention with green cardamom (P<0.001). ConclusionThis current study showed that the administration of green cardamom is a beneficial approach for improving of anthropometric, glycemic and androgen hormones, as well as, obesity and diabetes genes expression in PCOS women under low calorie diet. This trial was registered with the Iranian Clinical Trials Registry (registration number: IRCT20200608047697N1). 1 August, 2020; https://www.irct.ir/trial/48748

The effect of green cardamom on blood pressure and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta‐analysis of randomized clinical trials

“…Their main texts were assessed. Ten articles were excluded; among them, in two articles, there was no sufficient data to include them in the final quantitative analysis (Mohadeseh Aghasi et al, 2018; Daneshi‐Maskooni et al, 2017), in four, no relevant outcome was presented (Aghasi et al, 2019; Cheshmeh et al, 2021; Daneshi‐Maskooni et al, 2019; Yaghooblou et al, 2015), and in four, the study was conducted on animals (Abu‐Taweel, 2018; Bhaswant et al, 2015; Kumari & Dutta, 2013; Rahman et al, 2017). Finally, eight articles were included in our meta‐analysis (Azimi et al, 2014; Azimi et al, 2016; Daneshi‐Maskooni et al, 2018; Fatemeh et al, 2017; Kazemi et al, 2017; Winarsi & Susilowati, 2018; Zahedi et al, 2021; Zahedi et al, 2022).…”